Examine how the American Cancer Society’s national ACTS expansion is designed to simplify trial discovery, reduce logistical ...
In today’s ACT Brief, we examine why fragmented data systems continue to slow life sciences research, review how sponsor ...
In today’s ACT Brief, we cover the FDA approval of oral Wegovy based on Phase III OASIS 4 results, recap the most-read ...
If we can use AI or AI agents to automate those workflows, you can still run the same process, particularly as it relates to ...
Review the performance, engagement, and satisfaction metrics sponsors and CROs should track to determine whether operational ...
Learn how clinical operations leaders can build technology adoption, transform workflows, and cultivate digitally savvy ...
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
In today’s ACT Brief, we examine how sponsors are reassessing new engagement technologies to avoid increasing site burden, ...
Examine how evolving sourcing strategies, functional standardization, and system choices can help sponsors support sites more ...
In today’s ACT Brief, we examine new survey data revealing what patients value most in remote clinical trials, break down ...
Wegovy pill, the first oral GLP-1 for weight loss, is FDA-approved for reducing cardiovascular risks in adults. Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback